×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
INSM – insmed, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
INSM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/15
10:00 am
insm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
1/13
04:27 pm
insm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
1/12
06:02 pm
insm
Insmed CEO Will Lewis talks its rare disease drug pipeline [CNBC]
Medium
Report
Insmed CEO Will Lewis talks its rare disease drug pipeline [CNBC]
1/12
01:05 pm
insm
Insmed (NASDAQ:INSM) was given a new $205.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Insmed (NASDAQ:INSM) was given a new $205.00 price target on by analysts at Truist Financial Corporation.
1/10
10:52 pm
insm
Is It Too Late To Reassess Insmed (INSM) After Its Huge Share Price Surge? [Yahoo! Finance]
Medium
Report
Is It Too Late To Reassess Insmed (INSM) After Its Huge Share Price Surge? [Yahoo! Finance]
1/10
07:02 pm
insm
The Bull Case For Insmed (INSM) Could Change Following Bold 2025 Revenue Guidance Hike - Learn Why [Yahoo! Finance]
Medium
Report
The Bull Case For Insmed (INSM) Could Change Following Bold 2025 Revenue Guidance Hike - Learn Why [Yahoo! Finance]
1/9
07:37 am
insm
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/9
07:00 am
insm
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/13
04:04 pm
insm
Form 4 INSMED Inc For: Jan 12 Filed by: Lewis William
Low
Report
Form 4 INSMED Inc For: Jan 12 Filed by: Lewis William
1/13
04:03 pm
insm
Form 4 INSMED Inc For: Jan 09 Filed by: Flammer Martina M.D.
Low
Report
Form 4 INSMED Inc For: Jan 09 Filed by: Flammer Martina M.D.
1/12
04:58 pm
insm
Form 144 INSMED Inc Filed by: Lewis William
Low
Report
Form 144 INSMED Inc Filed by: Lewis William
1/9
07:01 am
insm
Form 8-K INSMED Inc For: Jan 09
Medium
Report
Form 8-K INSMED Inc For: Jan 09
1/8
05:40 pm
insm
Form 144 INSMED Inc Filed by: Bonstein Sara
Medium
Report
Form 144 INSMED Inc Filed by: Bonstein Sara
1/8
05:36 pm
insm
Form 144 INSMED Inc Filed by: Flammer Martina M.D.
Medium
Report
Form 144 INSMED Inc Filed by: Flammer Martina M.D.
1/8
05:28 pm
insm
Form 144 INSMED Inc Filed by: Flammer Martina M.D.
Medium
Report
Form 144 INSMED Inc Filed by: Flammer Martina M.D.
1/8
05:23 pm
insm
Form 144 INSMED Inc Filed by: Adsett Roger
Medium
Report
Form 144 INSMED Inc Filed by: Adsett Roger
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/3
Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis
40.6%
2/4 Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Goldman Sachs Group Inc from $33.00 to $46.00. They now have a "buy" rating on the stock. 12.6%
3/17 Insmed Incorporated (NASDAQ: INSM) had its price target lowered by analysts at Stifel Nicolaus from $55.00 to $45.00. They now have a "buy" rating on the stock. 12.6%
4/30 Insmed Reports First Quarter 2020 Financial Results and Provides Business Update 8.0%
10/11 Insmed Incorporated (NASDAQ: INSM) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.9%
4/2 Insmed Appoints Carol A. Schafer to its Board of Directors 7.1%
10/30 Form 10-Q INSMED Inc For: Sep 30 6.7%
4/20 Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020 6.5%
1/7 Form 4 INSMED Inc For: Jan 03 Filed by: SORIANO JOHN 6.1%
6/12 Form 3 INSMED Inc For: Jun 03 Filed by: GOLL JOHN 5.7%
2/4 Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Goldman Sachs Group Inc from $33.00 to $46.00. They now have a "buy" rating on the stock. 12.6%
3/17 Insmed Incorporated (NASDAQ: INSM) had its price target lowered by analysts at Stifel Nicolaus from $55.00 to $45.00. They now have a "buy" rating on the stock. 12.6%
4/30 Insmed Reports First Quarter 2020 Financial Results and Provides Business Update 8.0%
10/11 Insmed Incorporated (NASDAQ: INSM) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.9%
4/2 Insmed Appoints Carol A. Schafer to its Board of Directors 7.1%
10/30 Form 10-Q INSMED Inc For: Sep 30 6.7%
4/20 Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020 6.5%
1/7 Form 4 INSMED Inc For: Jan 03 Filed by: SORIANO JOHN 6.1%
6/12 Form 3 INSMED Inc For: Jun 03 Filed by: GOLL JOHN 5.7%
TOP News Decliners
2/25
Q4/2019 12/31/2019 EPS -0.590 ZacksConsensus -0.590 ActVsEst 0.000 - In-Line
-16.4%
5/7 Q1/2019 3/31/2019 EPS -0.960 ZacksConsensus -0.940 ActVsEst (0.020) - Miss -13.0%
8/1 Q2/2019 6/30/2019 EPS -0.810 ZacksConsensus -0.850 ActVsEst 0.040 - Beat -12.3%
2/26 Galapagos Ratings Downgrade, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] -8.1%
3/31 Form DEFA14A INSMED Inc -6.6%
8/2 Insmed, Inc. (INSM) CEO Will Lewis on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.1%
5/20 New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease -5.9%
3/7 Insmed Incorporated (NASDAQ: INSM) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.9%
3/5 Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -5.7%
1/16 Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock. -5.0%
5/7 Q1/2019 3/31/2019 EPS -0.960 ZacksConsensus -0.940 ActVsEst (0.020) - Miss -13.0%
8/1 Q2/2019 6/30/2019 EPS -0.810 ZacksConsensus -0.850 ActVsEst 0.040 - Beat -12.3%
2/26 Galapagos Ratings Downgrade, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] -8.1%
3/31 Form DEFA14A INSMED Inc -6.6%
8/2 Insmed, Inc. (INSM) CEO Will Lewis on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.1%
5/20 New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease -5.9%
3/7 Insmed Incorporated (NASDAQ: INSM) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.9%
3/5 Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -5.7%
1/16 Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock. -5.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: